Trial Profile
A Phase Ib/II Study of Guadecitabine (SGI-110) Plus Nivolumab in Refractory CIMP+ Metastatic Colorectal Cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Guadecitabine (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions
- 01 Apr 2021 Status changed from recruiting to withdrawn prior to enrolment.
- 25 Mar 2020 Planned End Date changed from 6 Jan 2023 to 30 Jan 2023.
- 25 Mar 2020 Planned primary completion date changed from 6 Jan 2022 to 30 Jan 2022.